Sponsor Pipeline

RayzeBio, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
7
Active Trials
3
Recruiting
1
Phase 3
7
Disease Areas
Active Trials by Phase
Phase 3
1
Phase 1/2
2
Phase 1
2
Early Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05477576 Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET… GEP-NET Recruiting
Phase 1/2
NCT06726161 Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify… Hepatocellular Carcinoma (HCC) Recruiting
NCT06590857 Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or… Metastatic Breast Cancer Active, Not Recruiting
Phase 1
NCT07165132 Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. GEP-NET Recruiting
NCT05595460 Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC SCLC,Extensive Stage Active, Not Recruiting
Early Phase 1
NCT07671092 Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC Metastatic Urothelial Carcinoma Not Yet Recruiting
NCT07671417 Imaging Study in Metastatic Clear Cell RCC. Metastatic Clear Cell Renal Cell Carcinoma Not Yet Recruiting
Disease Areas
Get alerts when RayzeBio, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free